Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F24%3A00001388" target="_blank" >RIV/61383082:_____/24:00001388 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/24:10483353

Result on the web

<a href="https://pubmed.ncbi.nlm.nih.gov/39079993/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/39079993/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41591-024-03153-w" target="_blank" >10.1038/s41591-024-03153-w</a>

Result language

angličtina

Original language name

Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.

Original language description

Gastric cancer is a leading cause of cancer-related deaths in China. Affecting more than 40% of the world's population, Helicobacter pylori is a major risk factor for gastric cancer. While previous clinical trials indicated that eradication of H. pylori could reduce gastric cancer risk, this remains to be shown using a population-based approach. We conducted a community-based, cluster-randomized, controlled, superiority intervention trial in Linqu County, China, with individuals who tested positive for H. pylori using a C-13-urea breath test randomly assigned to receiving either (1) a 10-day, quadruple anti-H. pylori treatment (comprising 20 mg of omeprazole, 750 mg of tetracycline, 400 mg of metronidazole and 300 mg of bismuth citrate) or (2) symptom alleviation treatment with a single daily dosage of omeprazole and bismuth citrate. H. pylori-negative individuals did not receive any treatment. We examined the incidence of gastric cancer as the primary outcome. A total of 180,284 eligible participants from 980 villages were enrolled over 11.8 years of follow-up, and a total of 1,035 cases of incident gastric cancer were documented. Individuals receiving anti-H. pylori therapy showed a modest reduction in gastric cancer incidence in intention-to-treat analyses (hazard ratio 0.86, 95% confidence interval 0.74-0.99), with a stronger effect observed for those having successful H. pylori eradication (hazard ratio 0.81, 95% confidence interval 0.69-0.96) than for those who failed treatment. Moderate adverse effects were reported in 1,345 participants during the 10-day treatment. We observed no severe intolerable adverse events during either treatment or follow-up. The findings suggest the potential for H. pylori mass screening and eradication as a public health policy for gastric cancer prevention.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30219 - Gastroenterology and hepatology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Nature Medicine

ISSN

1078-8956

e-ISSN

—

Volume of the periodical

30

Issue of the periodical within the volume

11

Country of publishing house

DE - GERMANY

Number of pages

11

Pages from-to

3250 - 3260

UT code for WoS article

001281040200001

EID of the result in the Scopus database

—